YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Key Points Interested in Lineage Cell Therapeutics, Inc.? Here are five stocks we like better. Pipeline progress: Lineage advanced preclinical programs in corneal disease, Type 1 diabetes and hearing loss, while Roche and Genentech continu…
Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q2 2026 MANAGEMENT VIEW * "Insights and milestones from the OpRegen program have allowed us to fuel the growth of a new and significantly more internally owned pipeline of cell thera…
What happened According to an SEC filing dated May 14, 2026, Broadwood Capital purchased 1,104,351 shares of STAAR Surgical Company.(NASDAQ:STAA) during the first quarter, an estimated $21.08 million transaction based on the quarter’s aver…
Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q1 2026 MANAGEMENT VIEW * Brian Culley (CEO, President & Director) highlighted platform expansion and new pipeline launches: "I do definitely want to highlight the successful expansi…
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.11 per share a year ago. These figures are adjusted for non-recurring…
Guardant Health (GH) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to a loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items. This…
Lineage Cell Therapeutics Inc. (NYSE:LCTX) is one of the 10 best penny stocks that could triple your money. On March 24, Lineage Cell Therapeutics Inc. (NYSE:LCTX) announced the launch of COR1, a new preclinical cell therapy program target…
Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q4 2025 MANAGEMENT VIEW * CEO Brian Culley opened the call highlighting recent warrant exercises that have further extended the company's cash runway and announced a positive result…
As February begins, major U.S. stock indexes have surged, with the Dow Jones Industrial Average climbing by 515 points and the S&P 500 nearing a record high. In such a robust market environment, investors might consider exploring opportuni…
As the Dow Jones Industrial Average hits an all-time high for the second consecutive day, investors are closely watching market dynamics and seeking opportunities in lesser-known segments. Penny stocks, while often considered a relic of pa…
Issued on behalf of Avant Technologies Inc. VANCOUVER, British Columbia, Nov. 19, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – The autologous cell therapy market surpassed $10.1 billion in 2025 as biotechnology companies race…
DelveInsight Business Research LLP The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), Tin…
Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q3 2025 MANAGEMENT VIEW * CEO Brian Culley opened with an update on OpRegen, highlighting that "Genentech opened 2 new clinical sites last month and 5 new clinical sites were opened…
Lineage Cell (LCTX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This q…
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Lineage Cell Therapeutics, Inc. is one of them. Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is a clinical-stage biotech company developin…
Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index rising 0.6% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Key Points GAAP revenue doubled in Q2 2025 compared to Q2 2024, significantly beating analyst expectations on a GAAP basis as Collaboration income (GAAP) also doubled compared to Q2 2024. Net loss (GAAP) increased sharply due to large non-…
Earnings Call Insights: Lineage Cell Therapeutics (LCTX) Q2 2025 MANAGEMENT VIEW * CEO Brian M. Culley highlighted sustained progress for OpRegen, noting "the anatomical and functional benefits, which we first reported have lasted for 3 ye…
LINEAGE CELL THERAPEUTICS REPORTS Q2 2025 RESULTS: REVENUE BEATS, LOSS WIDENS Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX [https://www.chartmill.com/stock/quote/LCTX]) reported its second-quarter 2025 financial results, delivering mixed…
Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Successfully Reduced-to-Practice Critical Aspect of Commercial-Scale, Cell-Based, GMP Production Processes First Chronic P…
Major earnings expected after the bell on Tuesday include: * CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]) * Inovio Pharmaceuticals (INO [https://seekingalpha.com/symbol/INO]) * Luminar Technologies (LAZR [https://seekingalpha.co…
Lineage Cell Therapeutics (NYSE:LCTX), Inc. (NYSE American:LCTX) announced Wednesday that shareholders approved all proposals presented at the company’s annual meeting held last Thursday. According to a press release statement based on the…
Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion siteEvidence of retinal structural improvement persisted out to 3 yearsAnatomical and functional improveme…
Participants Ioana Hone; Investor Relations; Lineage Cell Therapeutics Inc Brian Culley; Chief Executive Officer, Director; Lineage Cell Therapeutics Inc Jill Howe; Chief Financial Officer; Lineage Cell Therapeutics Inc William Wood; Analy…
In this article, we will take a detailed look at Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Ken Fisher and Corporate Insiders Are Buying These…
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript November 9, 2023 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.05. Operator: Welcome to the Lineage C…
CARLSBAD, Calif., August 03, 2023--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that i…
Patients enrolled were diagnosed with refractory, metastatic or locally advanced, non-small cell lung cancer (NSCLC), for whom there were no other suitable treatment options Five of eight patients treated (62.5%) had a best response of imm…
CARLSBAD, Calif., May 22, 2023--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the C…
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2023 Earnings Call Transcript May 11, 2023 Lineage Cell Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.03 EPS, expectations were $-0.02478. Operator: Welcome to the Li…
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was…
Additional RG6501 (OpRegen®) Phase 1/2a Clinical Study Results Presented at ARVO 2023 Enrolling Phase 2a Clinical Study of RG6501 (OpRegen) in Patients with GA Secondary to AMD Under Management of Genentech, a Member of the Roche Group Awa…
Award Will Support 1st Annual Spinal Cord Injury Investor Symposium To Be Held June 29, 2023 CARLSBAD, Calif., May 09, 2023--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology co…
Puma Biotech (PBYI) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring i…
CARLSBAD, Calif., May 04, 2023--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it w…
Preliminary Evidence of Durable Anatomical and Functional Improvements Following Administration of OpRegen Cells Extensive OpRegen Surgical Bleb Coverage of Areas of GA May Be Critical for Optimizing Patient Outcomes OCT Imaging With Segme…